Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (NYSE: DXR) announces Oregon Health & Science University (OHSU) as a second site for a COVID-19 clinical trial using its Blood Volume Analyzer (BVA) technology. This partnership follows the earlier collaboration with NYU Langone Health. The BVA-100 is FDA-cleared and quantifies blood components, aiding in patient treatment strategies. The trial aims to investigate the implications of COVID-19 as an endothelial disease, with findings from previous studies indicating significant reductions in ICU mortality. The study is led by Dr. Martin A. Schreiber at OHSU.
Daxor Corporation (NYSE: DXR) will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on October 13, 2020, at 3:00 PM ET. President and CEO Michael Feldschuh will provide insights on the company, including recent research from the Heart Failure Society of America, highlighting the BVA-100® blood test's cost-effectiveness and its potential to enhance patient lifespan in heart failure.
A Q&A session will follow the presentation. For more details, visit microcaprodeo.com.
Daxor Corporation (NYSE: DXR) recently presented new findings at the Heart Failure Society of America’s Annual Scientific Meeting regarding its BVA-100® blood test, which measures anemia in heart failure patients. The study revealed that 62% of hospitalized heart failure patients suffer from true anemia, often undetected by standard tests. Daxor's BVA-100® can significantly improve patient outcomes, reducing 30-day mortality by 82% and readmissions by 56%. The company is also developing next-gen measurement technologies under contracts with the US Department of Defense.
Daxor Corporation (NYSE: DXR) presented new data on the cost-effectiveness of its BVA-100 blood volume analysis technology for treating heart failure at the Heart Failure Society of America’s Annual Scientific Meeting 2020. The study found an incremental cost-effectiveness ratio (ICER) of $10,200, which is significantly lower than other therapies. This leads to an average life extension of 2.32 quality-adjusted life years (QALYs). Daxor's technology is noted for improving patient outcomes while being economically advantageous for healthcare systems.
Daxor Corporation (NYSE: DXR) announces new data from the Mayo Clinic demonstrating that its Blood Volume diagnostic test, BVA-100, significantly outperforms the common weight loss metric in assessing heart failure treatment progress. Presented at the HFSA Annual Scientific Meeting 2020, the study highlights that traditional weight loss does not predict clinical outcomes, while Daxor's technology has been shown to reduce heart failure mortality by over 80% and readmissions by over 56%. Daxor aims to integrate its technology into standard practice to enhance patient care.
Daxor Corporation (NYSE: DXR) will exhibit at the Heart Failure Society of America’s Virtual Annual Scientific Meeting from September 30 to October 6, 2020. The company plans to showcase its BVA-100® blood test, highlighting new data on heart failure management through two posters: ‘Red Cell Volume Phenotypes in Hospitalized Heart Failure Patients’ (Poster #132) and ‘Cost-effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure Patients’ (Poster #331). The event aims to promote Daxor’s technology and enhance heart failure outcomes.
Daxor Corporation (NYSE: DXR) will showcase innovative data at the Heart Failure Society of America's Virtual Annual Scientific Meeting from September 30 to October 6, 2020. The company will present its BVA-100® blood test, aimed at improving heart failure outcomes. Key presentations include 'Red Cell Volume Phenotypes in Hospitalized Heart Failure Patients' and 'Cost-effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure Patients.' CEO Michael Feldschuh emphasizes Daxor's commitment to enhancing heart failure treatment through advanced blood volume measurement technology.
Daxor Corporation (NYSE: DXR) announced its participation in the inaugural Sepsis Alliance Summit on September 17, 2020. CEO Michael Feldschuh will discuss the BVA-100 blood test's role in improving sepsis care through insights into volume derangements and capillary permeability in critically-ill patients. The BVA-100 test, linked to significant clinical benefits, has shown 66% lower mortality rates in patients receiving BVA-guided care. September is also National Sepsis Awareness Month, highlighting the urgent need to combat sepsis, which affects 1.7 million adults in the U.S. annually.
Daxor Corporation (NYSE: DXR) will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 PM ET. During this event, President & CEO Michael Feldschuh will present updates regarding the company's BVA-100 technology, a diagnostic tool for blood volume measurement. The conference runs from September 14-16, 2020, featuring opportunities for one-on-one meetings with investors. Daxor's technology aims to enhance treatment strategies and patient outcomes in critical medical conditions.
Daxor Corporation (NYSE: DXR) will present at the LD 500 Virtual Investor Conference from September 1-4, 2020. CEO Michael Feldschuh is scheduled to present on September 2 at 9:20 am ET, followed by a Q&A session. The presentation will cover updates on the company's diagnostic division and ongoing clinical trials. Investors can request one-on-one meetings with Feldschuh during the event. The presentation will be available for live streaming and replay here.